These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34337277)

  • 1. Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade.
    Brancatella A; Lupi I; Montanelli L; Ricci D; Viola N; Sgrò D; Antonangeli L; Sardella C; Brogioni S; Piaggi P; Molinaro E; Bianchi F; Aragona M; Antonuzzo A; Sbrana A; Lucchesi M; Chella A; Falcone A; Del Prato S; Elisei R; Marcocci C; Caturegli P; Santini F; Latrofa F
    J Endocr Soc; 2021 Sep; 5(9):bvab093. PubMed ID: 34337277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steroid treatment in the management of destructive thyrotoxicosis induced by PD1 blockade.
    Brancatella A; Pierotti L; Viola N; Lupi I; Montanelli L; Cremolini C; Piaggi P; Chella A; Antonuzzo A; Sgrò D; Antonangeli L; Sardella C; Brogioni S; Marcocci C; Santini F; Latrofa F
    Eur Thyroid J; 2022 Aug; 11(4):. PubMed ID: 35622442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A; Kottschade L; Ryder M
    Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
    [No Abstract]   [Full Text] [Related]  

  • 4. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
    Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
    Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Significance of Thyroid Autoantibodies in Differential Diagnosis and Predicting the Course of Programmed Cell Death Protein-1 Inhibitor-Induced Thyroid Dysfunction.
    Li L; Ding X; Zhang X; Kong S; Chen M
    Endocr Pract; 2024 Aug; ():. PubMed ID: 39216687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index.
    Pollack R; Ashash A; Cahn A; Rottenberg Y; Stern H; Dresner-Pollak R
    J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32668461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with immune-related thyroid dysfunction induced by PD-1/PD-L1 inhibitors in cancer patients: an observational study.
    Wei XC; Guo YY; Zhang Y; Bu YS; Zhang FY
    J Chemother; 2024 Jan; ():1-8. PubMed ID: 38240051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Permanent hypothyroidism following immune checkpoint inhibitors induced thyroiditis may be associated with improved survival: results of an exploratory study.
    Lee HJ; Manavalan A; Stefan-Lifshitz M; Schechter C; Maity A; Tomer Y
    Front Endocrinol (Lausanne); 2023; 14():1169173. PubMed ID: 37168978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical characteristics and risk factors of programmed death-1 inhibitors associated with thyroid gland injury].
    Gong WW; Zhou FY; Guo QH
    Zhonghua Nei Ke Za Zhi; 2023 Feb; 62(2):176-181. PubMed ID: 36740408
    [No Abstract]   [Full Text] [Related]  

  • 11. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
    Mazarico I; Capel I; Giménez-Palop O; Albert L; Berges I; Luchtenberg F; García Y; Fernández-Morales LA; De Pedro VJ; Caixàs A; Rigla M
    J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.
    Guaraldi F; La Selva R; Samà MT; D'Angelo V; Gori D; Fava P; Fierro MT; Savoia P; Arvat E
    J Endocrinol Invest; 2018 May; 41(5):549-556. PubMed ID: 29043574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoassay Interference on Thyroid Function Tests During Treatment with Nivolumab.
    Paragliola RM; Corsello A; Papi G; Melfa E; Urbani A; Pontecorvi A; Corsello SM; Carrozza C
    Thyroid; 2020 Jul; 30(7):1091-1094. PubMed ID: 32122271
    [No Abstract]   [Full Text] [Related]  

  • 14. Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade.
    Kobayashi T; Iwama S; Yamagami A; Yasuda Y; Okuji T; Ito M; Zhou X; Ando M; Onoue T; Miyata T; Sugiyama M; Hagiwara D; Suga H; Banno R; Hase T; Morise M; Ito T; Kikumori T; Inoue M; Ando Y; Masuda N; Kawashima H; Hashimoto N; Arima H
    J Clin Endocrinol Metab; 2022 Sep; 107(10):e4115-e4123. PubMed ID: 35918067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iodine excess and hyperthyroidism.
    Roti E; Uberti ED
    Thyroid; 2001 May; 11(5):493-500. PubMed ID: 11396708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume.
    Sakurai K; Fukazawa H; Arihara Z; Yoshida K
    Tohoku J Exp Med; 2010 Sep; 222(1):39-44. PubMed ID: 20814176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma.
    Koizumi Y; Hirooka M; Hiraoka A; Ochi H; Tanaka T; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Miyake T; Matsuura B; Michitaka K; Joko K; Abe M; Hiasa Y
    Endocr J; 2019 Sep; 66(9):787-792. PubMed ID: 31142692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graves' Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature.
    Brancatella A; Viola N; Brogioni S; Montanelli L; Sardella C; Vitti P; Marcocci C; Lupi I; Latrofa F
    Eur Thyroid J; 2019 Jul; 8(4):192-195. PubMed ID: 31602361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amiodarone: a common source of iodine-induced thyrotoxicosis.
    Martino E; Aghini-Lombardi F; Mariotti S; Bartalena L; Braverman L; Pinchera A
    Horm Res; 1987; 26(1-4):158-71. PubMed ID: 2885251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy.
    Luongo C; Morra R; Gambale C; Porcelli T; Sessa F; Matano E; Damiano V; Klain M; Schlumberger M; Salvatore D
    J Endocrinol Invest; 2021 Sep; 44(9):1927-1933. PubMed ID: 33576954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.